Want to see CERS full AI Analyst Report?
CERS Stock Chart & Stats
$2.93
$0.06(2.09%)
At close: 4:00 PM EDT
$2.93
$0.06(2.09%)
Day’s Range― - ―
52-Week Range$1.15 - $3.47
Previous CloseN/A
Volume2.51M
Average Volume (3M)2.58M
Market Cap
$473.58M
Enterprise Value$606.88
Total Cash (Recent Filing)$56.26M
Total Debt (Recent Filing)$76.80M
Price to Earnings (P/E)―
Beta1.78
Next Earnings
Oct 29, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding201,524,900
10 Day Avg. Volume2,048,169
30 Day Avg. Volume2,580,345
Financial Highlights & Ratios
PEG Ratio0.99
Price to Book (P/B)6.11
Price to Sales (P/S)1.90
P/FCF Ratio46.07
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$5.00Price Target Upside70.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.03
Revenue Forecast (FY)$252.78M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueINTERCEPT’s business is anchored in single-use processing sets and consumables that are required each treatment. This creates durable, procedure-linked recurring revenue and customer lock-in, supporting predictable demand, higher revenue visibility and repeatable cash generation as volumes scale.
Accelerating Product Revenue And Market PenetrationSustained double-digit product growth and raised guidance reflect accelerating adoption—especially large NA platelet kit volume gains and international expansion. Deeper market penetration supports scale benefits for gross profit and strengthens the recurring consumable base over a multi-quarter horizon.
Improving Profitability Trends And Operating DisciplineEight consecutive positive adjusted EBITDA quarters and declining operating spend indicate durable operating leverage. Sustained adjusted-EBITDA profitability and narrowing GAAP losses improve odds of consistent cash conversion and reduce reliance on external financing over time.
Bears Say
Elevated Financial LeverageDebt materially exceeding equity raises financing and covenant risk, limiting strategic flexibility. Elevated leverage increases sensitivity to cash flow volatility, raises interest/covenant pressure after the credit amendment, and constrains capital allocation until profitability and stable cash generation are sustained.
Volatile And Weak Cash GenerationInconsistent conversion of earnings to cash and marginal/negative free cash flow force reliance on credit lines or financing for working capital and growth. This undermines durable self-funding, complicates deleveraging, and raises execution risk if revenue or margin trends slow.
Margin Pressure And Regulatory/timing RiskPersistently lower gross margins from inflation, tariffs and FX reduce long-term profitability headroom. Simultaneously, timing uncertainty for the INTERCEPT red blood cell CE Mark and the lumpy IFC rollout risk delaying a major revenue inflection and prolonging margin recovery and cash-flow stability.
Cerus News
CERS FAQ
What was Cerus Corporation’s price range in the past 12 months?
Cerus Corporation lowest stock price was $1.15 and its highest was $3.47 in the past 12 months.
What is Cerus Corporation’s market cap?
Cerus Corporation’s market cap is $473.58M.
When is Cerus Corporation’s upcoming earnings report date?
Cerus Corporation’s upcoming earnings report date is Oct 29, 2026 which is in 78 days.
How were Cerus Corporation’s earnings last quarter?
Cerus Corporation released its earnings results on Jul 30, 2026. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.013 by $0.003.
Is Cerus Corporation overvalued?
According to Wall Street analysts Cerus Corporation’s price is currently Undervalued.
Does Cerus Corporation pay dividends?
Cerus Corporation does not currently pay dividends.
What is Cerus Corporation’s EPS estimate?
Cerus Corporation’s EPS estimate is -0.02.
How many shares outstanding does Cerus Corporation have?
Cerus Corporation has 201,524,900 shares outstanding.
What happened to Cerus Corporation’s price movement after its last earnings report?
Cerus Corporation reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.013. Following the earnings report the stock price went down -25.606%.
Which hedge fund is a major shareholder of Cerus Corporation?
Currently, no hedge funds are holding shares in CERS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cerus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (70.65% Upside)
$5.00 (70.65% Upside)
Blogger Sentiment
Bullish
CERS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $53.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
120.86%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.70%
Trailing 12-Months
Company Description
Cerus Corporation
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.
CERS Company Deck
CERS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple clear commercial and operational positives: strong Q1 top-line performance (24% product revenue growth), raised full-year guidance, robust IFC/platelet momentum, continued positive adjusted EBITDA, disciplined operating expense control, and advancing regulatory/product milestones (illuminator PMA submission and RBC trial readout). Offsetting these positives are persistent margin headwinds (gross margin down to 52%), macro pressures (inflation, tariffs, FX), regional logistical risks (Middle East), working capital-driven cash use, and timing uncertainty around the red blood cell CE Mark and the lumpy nature of IFC rollout. On balance, the highlights—notably recurring revenue growth, improved profitability trends, and strengthened guidance—outweigh the lowlights, though management cautions about margin and timing risks.View all CERS earnings summariesCERS Stock 12 Month Forecast
Average Price Target
$5.00
▲(70.65% Upside)
Technical Analysis
Tactile Systems Technology
―
Viemed Healthcare
―
Brainsway
―
Outset Medical
―
908 Devices
―
Ownership Overview
5.72% Insiders
12.85% Mutual Funds
5.25% Other Institutional Investors
55.76% Public Companies and
Individual Investors